Teva Pharmaceutical Industries LTD Form 4 insider transactions

Eliyahu Sharon Kalif, Executive Vice President and Chief Financial Officer of Teva Pharmaceutical Industries Ltd., sold 55,775 ordinary shares for approximately $17.08 per share as part of a pre-scheduled Rule 10b5-1 trading plan.

Teva Pharmaceutical Industries Ltd. Director Sol J. Barer reported the vesting of previously granted restricted share units and the acquisition of new units, alongside a disposition of ordinary shares.

Teva Pharmaceutical Industries Ltd. Director Janet S. Vergis reported the vesting of 9,632 restricted share units into ordinary shares and the grant of 14,492 new restricted share units.

Teva Pharmaceutical Industries Ltd. Director Tal Zvi Zaks acquired 9,632 ordinary shares through the vesting of restricted share units and received a new grant of 14,492 restricted share units.

Teva Pharmaceutical Industries Ltd. Director Varda Shalev reported the vesting of 9,632 restricted share units and the grant of 14,492 new restricted share units, alongside the disposition of 22,504 ordinary shares.

A Teva Pharmaceutical Industries Ltd. director, Ronit Satchi-Fainaro, reported the vesting of previously granted restricted share units (RSUs) and the acquisition of new RSUs as part of her compensation.

Teva Pharmaceutical Industries Ltd. Director Perry Nisen disclosed the vesting of previously granted restricted share units into ordinary shares and the grant of new restricted share units, aligning his interests with shareholders.

Gerald M. Lieberman, a Director at Teva Pharmaceutical Industries Ltd., reported the vesting of 9,632 restricted share units and the grant of an additional 14,492 restricted share units.

Teva Pharmaceutical Industries Ltd. Director Amir Elstein disclosed the vesting of previously granted restricted share units and the grant of new restricted share units, aligning his interests with shareholders.

Teva Pharmaceutical Industries Ltd. Director Rosemary A. Crane reported the vesting of previously granted restricted share units and the acquisition of new units, increasing her direct beneficial ownership of ordinary shares.

Teva Pharmaceutical Industries Ltd. announced that Director Chen Lichtenstein was granted 14,492 restricted share units, which will vest on June 5, 2026.

Teva Pharmaceutical Industries Ltd. Director Roberto Mignone reported the vesting and acquisition of 9,632 ordinary shares from restricted share units, alongside a new grant of 14,492 restricted share units.

Teva Pharmaceutical Industries Ltd.'s President and CEO, Richard D. Francis, was granted 52,173 Restricted Share Units (RSUs) on June 5, 2025, aligning his incentives with shareholder value.

Teva Pharmaceutical Industries Ltd.'s EVP of Global Operations, Matthew Shields, reported the vesting of 16,195 restricted share units and a subsequent sale of 6,206 ordinary shares to cover tax obligations.

Evan Lippman, EVP of Business Development at Teva Pharmaceutical Industries, was granted restricted share units on May 14, 2025, according to a Form 4 filing.

Mark Sabag, Executive Vice President at Teva Pharmaceutical Industries, reported the sale of 337,915 ordinary shares at an average price of $18.0439.

Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the vesting and acquisition of restricted share units, as well as the disposition of ordinary shares, on March 5, 2025.

Christine Fox, EVP, Head of U.S. Commercial at Teva Pharmaceutical Industries, was granted 71,278 restricted share units on March 5, 2025, according to a Form 4 filing.

David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, was granted 56,603 restricted share units on March 5, 2025, according to a Form 4 filing.

Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reports the vesting of restricted share units and acquisition of ordinary shares.

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, was granted 78,616 restricted share units on March 5, 2025, according to a Form 4 filing.

Mark Sabag, an Executive Vice President at Teva Pharmaceutical Industries, reported the vesting and disposal of restricted share units and acquisition of additional restricted share units on March 5, 2025.

EVP, Global Operations at Teva Pharmaceutical Industries, Matthew Shields, reports the acquisition of 69,182 restricted share units.

Placid Jover, Executive Vice President and Chief Human Resources Officer at Teva Pharmaceutical Industries, was granted 56,603 restricted share units on March 5, 2025, according to a Form 4 filing.

Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports the sale of ordinary shares and acquisition of restricted share units (RSUs) under a pre-arranged trading plan.

Richard D. Francis, President and CEO of Teva Pharmaceutical Industries, reports the acquisition of 169,811 restricted share units on March 5, 2025.

Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports transactions involving ordinary shares and restricted share units.

EVP Christine Fox of Teva Pharmaceutical Industries sold shares to cover tax obligations related to vesting restricted share units, as per a pre-arranged Rule 10b5-1 trading plan.

David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, sold shares to cover tax withholding obligations related to vesting restricted share units.

Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reports the vesting and disposal of restricted share units, resulting in changes to his beneficial ownership of ordinary shares.